Related Experiment Video
Updated: Dec 4, 2025
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
Nicolai Skovbjerg Arildsen1,2, Ingrid Hedenfalk1
1Division of Oncology, Department of Clinical Sciences, Lund and Lund University Cancer Center, Lund University, Lund, Sweden.
Abstract:
Ovarian clear cell carcinomas (OCCC) constitute a rare subtype of epithelial ovarian cancer, lacking efficient treatment options. Based on previous studies, we assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer (HGSOC) cell line, Caov3. We used the Rho GTPase interfering drug CID-1067700 as a control. All OCCC cell lines were more sensitive to single-agent simvastatin than the HGSOC cells, while all cell lines were less sensitive to CID-1067700 than to simvastatin. Combinations of carboplatin and simvastatin were generally antagonistic. Most treatments inhibited migration, while only simvastatin and CID-1067700 also disrupted actin organization in the OCCC cell lines. All treatments induced a G1 arrest in JHOC-5 and TOV-21G cells. Treatments with simvastatin consistently reduced c-Myc protein expression in all OCCC cell lines and displayed evidence of causing both caspase-mediated apoptotic cell death and autophagic response in a cell line dependent manner. Differences between cell lines in response to the treatments were observed and such differences, including e. g. prior treatment, should be investigated further. Conclusively, simvastatin efficiently controlled OCCC proliferation and migration, thus showing potential as a candidate drug for the treatment of OCCC.
Insights
Simvastatin effectively reduced proliferation and migration in ovarian clear cell carcinoma (OCCC) cells, showing promise as a potential treatment. Further research is needed to explore cell line variations in response to simvastatin therapy.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Ovarian clear cell carcinoma (OCCC) is a rare epithelial ovarian cancer subtype with limited treatment options.
- Simvastatin, a Rho GTPase interfering drug, has shown potential anti-cancer effects.
- Understanding OCCC cell line sensitivity to novel therapeutic agents is crucial.
Purpose of the Study:
- To evaluate the anti-proliferative and anti-migratory effects of simvastatin in OCCC cell lines.
- To compare simvastatin's efficacy against a control drug (CID-1067700) and carboplatin combination.
- To investigate simvastatin's impact on cell cycle, actin organization, and molecular markers in OCCC.
Main Methods:
- Utilized three OCCC cell lines (JHOC-5, OVMANA, TOV-21G) and one high-grade serous ovarian cancer (HGSOC) cell line (Caov3).
- Assessed cell proliferation, migration, actin organization, and G1 cell cycle arrest.
- Measured c-Myc protein expression and investigated apoptotic and autophagic responses.
Main Results:
- OCCC cell lines were more sensitive to simvastatin than the HGSOC cell line.
- Simvastatin and CID-1067700 inhibited migration and disrupted actin organization in OCCC cells.
- Simvastatin reduced c-Myc expression and induced apoptosis and autophagy in a cell-dependent manner, while carboplatin combinations were antagonistic.
Conclusions:
- Simvastatin demonstrates significant potential as a therapeutic agent for controlling OCCC proliferation and migration.
- Observed variations in cell line responses highlight the need for further investigation into treatment individualization.
- Simvastatin's multifaceted effects on OCCC cells warrant its consideration for clinical development.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents